1 Cheap UK stock I’d buy to start generating passive income today

With a yield of 4.2% and 10 years of 21% dividend hikes under its belt, I’ve got my eye on this cheap UK stock for my passive income portfolio.

| More on:

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

UK stocks have largely had a terrific run so far this year. But despite the British stock market’s upward trajectory, plenty of cheap shares are still being left behind. Some even pay attractive yields, which opens the door to potentially ample passive income.

Take Bioventix (LSE:BVXP) as an example. Year-to-date, shares are actually down almost 13%, raising the biotech group’s yield to 4.2% while dragging the price-to-earnings (P/E) ratio down to 23. The latter may not scream bargain. However, considering that this UK stock has historically traded at a much higher premium, it looks like a buying opportunity may have emerged.

Understanding Bioventix

The world of biotech can be quite daunting to explore. After all, modern medical research is a complex field with many businesses chasing similar opportunities. Fortunately, Bioventix is a very niche but incredibly critical business that makes it easier to understand.

The firm’s a manufacturer of monoclonal antibodies used for detecting diseases throughout the human body, such as cancer and heart disease. Labs and hospitals around the world are in need of a constant supply, which Bioventix is more than happy to provide. And over the years, its translated into some impressive financials.

Annual revenue growth’s been a modest yet consistent 8% over the last five years – a trend that’s expected to continue. But the stars of the show are margins, with operating profitability standing at a whopping 79%!

That’s enabled Bioventix to be entirely debt-free despite operating in a capital-intensive industry. It’s also resulted in a cash-rich balance sheet as well as an impressive track record of hiking dividends. In fact, shareholder payouts have been hiked by an average of 21.4% for 10 years in a row so far.

Risk vs reward

It’s clear from the firm’s track record that Bioventix has been a terrific source of passive income over the last decade. And when paired with a 540% increase in share price over the same period, the stock’s also been a stellar investment. But now the question is whether the company can continue this upward trajectory?

From a customer demand perspective, Bioventix doesn’t seem to have any major issues. Manufacturing antibodies is difficult. And while there are alternatives, the group appears to have made itself stand out versus its peers in terms of product quality.

However, this doesn’t automatically make it a guaranteed future success story. The firm’s still exposed to demand cycles from customers. And in its latest interim results, Bioventix is having to tackle some issues on this front. Its Troponin antibodies used to assess heart damage have suffered from softer demand of late, resulting in lower-than-expected revenue generation.

Long-term demand remains promising, but temporary weakness within a small-cap AIM stock can be significant enough to trigger volatility. Nevertheless, with management expanding its portfolio of antibodies for use in new tests for diseases such as Alzheimer’s, the risks may be worth taking. At least, that’s what I think. And it’s why I’m planning to snap up some shares for my passive income portfolio once I have more capital at hand.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has recommended Bioventix Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

artificial intelligence investing algorithms
Investing Articles

BP shares are up 7% in a week but still yield 5.4% with a P/E of just 6! Time for me to buy?

Harvey Jones thought BP shares looked unmissable value when he bought them in September. Now he's wondering whether he should…

Read more »

Investing Articles

2 UK shares for value investors to consider buying

From a buying perspective, Stephen Wright thinks this looks like a good time to consider shares in cruise company Carnival…

Read more »

Investing Articles

After crashing 80% is this former stock market darling the best share to buy today?

Harvey Jones is looking for the best shares to buy in October and thinks this former growth star could finally…

Read more »

Investing Articles

Is the Stocks and Shares ISA safe?

With public spending in need of a boost, Stocks and Shares ISAs risk being altered. Does this Foolish author think…

Read more »

Investing Articles

When I look for dividend shares to buy, should I just go for the biggest yields?

The FTSE 100 is having a strong year in 2024 so far. But there are still some great yields offered…

Read more »

Investing Articles

What on earth’s going on with the IAG share price?

The IAG share price has fallen 10% over the past week, so what exactly is happening? Dr James Fox spies…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

Here’s why the stock market shouldn’t care about Tesla’s delivery numbers

The market reacted badly to Tesla’s quarterly deliveries coming in below expectations, causing the stock to fall. Stephen Wright thinks…

Read more »

Young Caucasian man making doubtful face at camera
Investing For Beginners

Here’s the average return from the UK’s FTSE 100 index over the last 20 years

Many British investors have money in FTSE tracker funds. But is that a smart move given the historical returns from…

Read more »